Austedo's drug class is a vmat2 inhibitor (vesicular monoamine transporter 2 inhibitor) What is tardive dyskinesia (td) and chorea associated with huntington’s disease She added, “these data articulate patient experience and further validate clinical research showing how austedo or austedo xr can help people living with tardive dyskinesia improve their symptoms while maintaining their mental health, something we care deeply about in our mission at teva to improve the lives of patients.” The most common adverse reactions for austedo (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia. Austedo standard and xr tablets are currently indicated for adults for the treatment of chorea in huntington disease and tardive dyskinesia Austedo is the first vmat2 inhibitor approved by the us food and drug administration for adults with tardive dyskinesia
3 it is not currently approved for pediatric patients Overall, the findings showed that both treatments are associated with reduced severity of involuntary movements and improvements. Resources for each step of the treatment journey with austedo xr teva is committed to supporting your patients with tardive dyskinesia (td) and their care partners.
OPEN
